Wendy G. Lane, MD, MPH and Rebecca R. Seltzer, MD, MHS
If it is ethically justifiable for clinicians to err by overreporting suspected abuse and neglect, we must fairly distribute benefits and harms among all children and families.
AMA J Ethics. 2023;25(2):E133-140. doi:
10.1001/amajethics.2023.133.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.